[Asia Economy Reporter Hyunseok Yoo] AndyForce is showing strong performance. It appears that the news of the Ministry of Food and Drug Safety (MFDS) granting export approval for the influenza virus molecular diagnostic kit has had an impact.
As of 2:25 PM on the 27th, AndyForce was trading at 4,975 KRW, up 10.67% (475 KRW) compared to the previous trading day.
AndyForce announced that it had obtained export approval from the MFDS for the influenza virus molecular diagnostic kit ‘ND Influenza A/B Detection Kit’ the day before. Using the real-time polymerase chain reaction (RT-PCR) method, it can simultaneously confirm infection with influenza types A and B within 2 hours.
An AndyForce official stated, “This export approval for the influenza molecular diagnostic kit is essential for obtaining export approval for the two types of COVID-19 and influenza simultaneous diagnostic kits developed in July,” adding, “This export approval will also accelerate the export approval process for the two simultaneous diagnostic kits that have already been developed.”
He continued, “AndyForce is currently pursuing FDA approval in the United States for molecular diagnostic (RT-PCR) and antigen-antibody diagnostic kits for COVID-19, and plans to apply for FDA approval for the recently developed simultaneous diagnostic kits as well,” adding, “Through a diverse diagnostic kit portfolio, we aim to become a leader in the global diagnostic kit market.”
In July, AndyForce completed the development of two molecular diagnostic kits capable of simultaneous COVID-19 and influenza diagnosis: ‘ND COVID-19 Flu’ and the rapid diagnostic kit ‘ND COVID-19 Flu Rapid Kit.’
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
